Integra Therapeutics, a Barcelona, Spain-based biotechnology company that is creating next-generation gene writing tools to boost the efficiency and safety of advanced therapies, raised €4.5m in the first round of funding.
Backers included Advent France Biotechnology, Invivo Capital and Takeda Ventures.
The company intends to use the funds to develop an innovative gene writing platform with the potential to make advanced therapies safer and more effective.
Founded in late 2020 as a spin-off of Pompeu Fabra University (UPF) based on technology developed in the Translational Synthetic Biology Lab led by Dr Marc Güell (EMBO Young Investigator, National Research Award for Young Talent and co-founder of two biotech firms) and Avencia Sánchez-Mejías of Pompeu Fabra University, Integra Tx is a biotechnology company that is creating next-generation gene writing tools to make advanced therapies safer and more effective.
The funds raised in this round will allow Integra Tx to complete the prototype of the new gene writing technology platform, carry out preclinical validation using in vivo and ex vivo models, and manage its patent portfolio in 2022 and 2023. After that, the company plans to open a Series A round to seek regulatory approval and carry out clinical trials